Oral SQ House Dust Mite Immunotherapy Reduces Allergic Rhinitis Symptoms in Teens

A total of 946 study participants, including 302 adolescents aged 12-17 years, took part in the trial
A total of 946 study participants, including 302 adolescents aged 12-17 years, took part in the trial

ATLANTA, GA—The oral SQ house dust mite (HDM) sublingual immunotherapy (SLIT)-tablet, an allergy immunotherapy tablet, reduces house dust mite (HDM) allergic rhinitis among adolescents after 1 year of treatment, according to findings from a post-hoc subgroup analysis of data from a randomized, placebo-controlled, Phase 3 clinical trial in Japan, presented at the 2017 AAAAI Annual Meeting.

“HDM SLIT-tablets were efficacious in adolescents 12–17 years old with HDM allergic rhinitis,” said lead study author Kaare Lund, PhD, of ALK Abelló, Copenhagen, Denmark. “Efficacy in adolescents and adults were similar. Treatment was well-tolerated and there were no signals of differential tolerability profiles between adults and adolescents.”

HDM allergy is common among children and teenagers, Dr. Lund noted. The authors enrolled 946 study participants, including 302 adolescents aged 12–17 years. Participants were randomly assigned to receive placebo or one of two doses of HDM SLIT-tablets (6 SQ-HDM or 12 SQ-HDM). Electronic diaries were used to collect efficacy data during a run-in phase, a treatment period, and an evaluation period that ran concurrently with the final 8 weeks of treatment. Total combined rhinitis score (TCRS) was assessed using 4 rhinitis symptoms and medication score.

“In the efficacy assessment period after 1 year of treatment, the adjusted mean TCRS was 4.0 [with the 6 SQ dose], 4.1 [with 12 SQ] and 5.1 with placebo, implying absolute differences of 1.1 (95% CI: 0.2–2.0; P=0.020) and 1.0 (95% CI: 0.1–1.9; P=0.037) between the active groups and placebo among the adolescents,” Dr. Lund reported. “The adjusted mean rhinitis, conjunctivitis, rhinoconjunctivitis, and quality of life scores in adolescent subjects were also in favor of active treatment and similar to those in adult subjects (18–64 years old).”